LP
CBIO

LMR Partners’s Crescent Biopharma CBIO Stock Holding History

LMR Partners’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-141
Closed -$3.97K – 1375
2024
Q2 		$3.97K Hold
141
– – ﹤0.01% 1048
2024
Q1 		$42.3K Buy
+141
New +$42.1K ﹤0.01% 995
2021
Q3 		– Sell
-229
Closed -$53K – 1074
2021
Q2 		$53K Buy
+229
New +$58.3K ﹤0.01% 983
2021
Q1 		– Sell
-105
Closed -$40K – 1000
2020
Q4 		$40K Sell
105
-45
-30% -$15.8K ﹤0.01% 468
2020
Q3 		$46K Hold
150
– – ﹤0.01% 392
2020
Q2 		$57K Buy
+150
New +$42.5K ﹤0.01% 526
2014
Q3 		– Sell
-197
Closed -$166K – 390
2014
Q2 		$166K Buy
+197
New +$196K 0.01% 415

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

LMR Partners's CBIO Position: Q3 2024 in Review

LMR Partners sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 141 shares — an estimated $3.97K sold.

LMR Partners first reported a position in CBIO in Q2 2014 and held it in 7 quarters. The position peaked at $166K in Q2 2014. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

  • LMR Partners reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
  • LMR Partners sold 141 Crescent Biopharma shares in Q3 2024, an estimated $3.97K.
  • LMR Partners first reported a position in Crescent Biopharma in Q2 2014 and held it in 7 quarters.
  • LMR Partners's Crescent Biopharma position peaked at $166K in Q2 2014.
  • 36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.